Serum level of proteins involved in apoptosis and autophagy in patients with type 2 diabetes and non-alcoholic fatty liver disease

Aim of the study was to estimate the blood serum level of microtubule-associated protein 1 light chain 3 alpha (MAP1LC3alpha), beclin-1 (BECN-1), Bcl-2 (BCL-2), caspase-3 (CASP3) and autophagy related 5 (ATG-5) protein as potential markers of liver fibrosis in type 2 diabetes (T2D) patients with non-alcoholic fatty liver disease (NAFLD).

Material and methods. A single center cross-sectional observational study was performed. Seventy four patients with T2D and NAFLD were included, 23 men and 51 women, aged 18 to 74 years. Transient elastography was used for the assessment of liver fibrosis. The severity of fibrosis was estimated using the Metavir sсore. In addition, indirect liver fibrosis indices APRI and FIB-4 were calculated. Serum concentration of MAP1LC3alpha, BECN-1, BCL-2, CASP and ATG-5 was measured by ELISA. We applied ROC analysis to assess the value of studied indicators in diagnosis of liver fibrosis.

Results. Liver fibrosis stage F1 was verified in 16 subjects, stage F2 in 12, stage F3 in 7, and stage F4 in 19 individuals. Patients with advanced liver fibrosis (stage 3-4) when compared to those without fibrosis (stage 0–2) had higher content of MAP1LC3alpha (p = 0.01) and BECN-1 (p = 0.01). There were no significant differences in the level of BCL-2, CASP3 and ATG-5 between patients with different severity of fibrosis. In the ROC analysis, MAP1LC3alpha and BECN-1 showed significance for the diagnosis of severe liver fibrosis, which, however, did not exceed that of the APRI index.

Conclusions. In patients with T2D and NAFLD, serum levels of MAP1LC3alpha and BECN-1 are associated with severe liver fibrosis.

1. Kouroumalis E., Voumvouraki A., Augoustaki A., Samonakis D.N. Autophagy in liver diseases. World J. Hepatol. 2021;13(1):6–65. doi: 10.4254/wjh.v13.i1.6

2. Czaja M.J. Function of autophagy in nonalcoholic fatty liver disease. Dig. Dis. Sci. 2016;61(5):1304– 1313. doi: 10.1007/s10620-015-4025-x

3. Hernández-Gea V., Ghiassi-Nejad Z., Rozenfeld R., Gordon R., Fiel M.I., Yue Z., Czaja M.J., Friedman S.L. Autophagy releases lipid that promotes fibrogenesis by activated hepatic stellate cells in mice and in human tissues. Gastroenterology. 2012;142(4):938– 946. doi: 10.1053/j.gastro.2011.12.044

4. Ding H., Ge G., Tseng Y., Ma Y., Zhang J., Liu J. Hepatic autophagy fluctuates during the development of non-alcoholic fatty liver disease. Ann. Hepatol. 2020;19(5):516–522. doi: 10.1016/j.aohep.2020.06.001

5. Tong M., Zheng Q., Liu M., Chen L., Lin Y.H., Tang S.G., Zhu Y.M. 5-methoxytryptophan alleviates liver fibrosis by modulating FOXO3a/miR-21/ATG5 signaling pathway mediated autophagy. Cell. Cycle. 2021;20(7):676–688. doi: 10.1080/15384101.2021.1897241

6. Lodder J., Denaës T., Chobert M.N., Wan J., El-Benna J., Pawlotsky J.M., Lotersztajn S., Teixeira-Clerc F. Macrophage autophagy protects against liver fibrosis in mice. Autophagy. 2015;11(8):1280–1292. doi: 10.1080/15548627.2015.1058473

7. He H., Dang Y., Dai F., Guo Z., Wu J., She X., Pei Y., Chen Y., Ling W., Wu C., … Yu L. Post-translational modifications of three members of the human MAP1LC3 family and detection of a novel type of modification for MAP1LC3B. J. Biol. Chem. 2003;278(31):29278–29287. doi: 10.1074/jbc.M303800200

8. Wang L., Xu M., Jones O.D., Li Z., Liang Y., Yu Q., Li J., Wu Y., Lei X., He B., … Xu X. Nonalcoholic fatty liver disease experiences accumulation of hepatic liquid crystal associated with increasing lipophagy. Cell Biosci. 2020;10:55. doi: 10.1186/s13578-020-00414-2

9. Kotsafti A., Farinati F., Cardin R., Cillo U., Nitti D., Bortolami M. Autophagy and apoptosis-related genes in chronic liver disease and hepatocellular carcinoma. BMC Gastroenterol. 2012;12:118. doi: 10.1186/1471-230X-12-118

10. Teng K.Y., Barajas J.M., Hu P., Jacob S.T., Ghoshal K. Role of B cell lymphoma 2 in the regulation of liver fibrosis in miR-122 knockout mice. Biology (Basel). 2020;9(7):157. doi: 10.3390/biology9070157

11. Ehsan N.A., Mosbeh A.M., Elkhadry S.W., Gomaa A.I., Elsabaawy M.M., Elazab D.S. Altered protein and gene expression of beclin-1 correlates with poor prognosis of Hcv-Associated hepatocellular carcinoma in Egyptian patients. Asian Pac. J. Cancer Prev. 2021;22(4):1115–1122. doi: 10.31557/APJCP.2021.22.4.1115

12. Zhang S., Xu M., Zhang W., Liu C., Chen S. Natural polyphenols in metabolic syndrome: protective mechanisms and clinical applications. Int. J. Mol. Sci. 2021;22(11):6110. doi: 10.3390/ijms22116110

13. Pop C., Salvesen G.S. Human caspases: activation, specificity, and regulation. J. Biol. Chem. 2009;284(33):21777–21781. doi: 10.1074/jbc.R800084200

14. Thapaliya S., Wree A., Povero D., Inzaugarat M.E., Berk M., Dixon L., Papouchado B.G., Feldstein A.E. Caspase 3 inactivation protects against hepatic cell death and ameliorates fibrogenesis in a diet-induced NASH model. Dig. Dis. Sci. 2014;59(6):1197–1206. doi: 10.1007/s10620-014-3167-6

15. Dedov I.I., Shestakova M.V., Mayorov A.Yu., Mokrysheva N.G., Vikulova O.K., Galstyan G.R., Kuraeva T.L., Peterkova V.A., Smirnova O.M., Starostina E.G., … Shestakova E.A. Standards of specialized diabetes care. Sakharnyy diabet = Diabetes Mellitus. 2021;24(1s):1–148. [In Russian]. doi: 10.14341/DM12802

16. Bohn M.J., Babor T.F., Kranzler H.R. The Alcohol Use Disorders Identification Test (AUDIT): validation of a screening instrument for use in medical settings. J. Stud. Alcohol. 1995;56(4):423–432. doi: 10.15288/jsa.1995.56.423

17. Ivashkin V.T., Mayevskaya M.V., Pavlov Ch.S., Tikhonov I.N., Shirokova Ye.N., Buyeverov A.O., Drapkina O.M., Shulpekova Yu.O., Tsukanov V.V., Mammayev S.N., Mayev I.V., Palgova L.K. Diagnostics and treatment of non-alcoholic fatty liver disease: clinical guidelines of the Russian Scientific Liver Society and the Russian gastroenterological association. Rossiyskiy zhurnal gastroenterologii, gepatologii, koloproktologii = Russian Journal of Gastroenterology, Hepatology, Coloproctology. 2016;(2):24–42. [In Russian]. doi: 10.22416/1382-4376-2016-26-2-24-42

18. Castéra L., Vergniol J., Foucher J., le Bail B., Chanteloup E., Haaser M., Darriet M., Couzigou P., de Lédinghen V. Prospective comparison of transient elastography, Fibrotest, APRI, and liver biopsy for the assessment of fibrosis in chronic hepatitis C. Gastroenterology. 2005;128(2):343–350. doi: 10.1053/j.gastro.2004.11.018

19. Vallet-Pichard A., Mallet V., Nalpas B., Verkarre V., Nalpas A., Dhalluin-Venier V., Fontaine H., Pol S. FIB-4: an inexpensive and accurate marker of fibrosis in HCV infection. Comparison with liver biopsy and fibrotest. Hepatology. 2007;46(1):32–36. doi: 10.1002/hep.21669

20. Wai C.T., Greenson J.K., Fontana R.J., Kalbfleisch J.D., Marrero J.A., Conjeevaram H.S., Lok A.S. A simple noninvasive index can predict both significant fibrosis and cirrhosis in patients with chronic hepatitis C. Hepatology. 2003;38(2):518–526. doi: 10.1053/jhep.2003.50346

21. Narkevich A.N., Vinogradov K.A. Methods for determining the minimum required sample size in medical research. Sotsial’nyye aspekty zdorov’ya naseleniya = Social Aspects of Population Health. 2019;65(6):1–10. [In Russian]. doi: 10.21045/2071-5021-2019-65-6-10